AMD

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.

The investigators explored the effects of the following covariates on development of AMD: sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.

According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

6-Month results underscore treatment safety with suprachoroidally injected ABBV-RGX-314 for nAMD

According to the company, a pair of presentations at the American Society of Retina Specialists annual meeting in Seattle highlight CLS-AX as a promising wet AMD treatment with a new mechanism of action and the potential for longer duration of effect than current therapies.

The company noted at the American Society of Retina Specialists meeting in Seattle the phase 2 Dose Expansion (N=50) initial interim efficacy and safety data presentation expected at medical conference in H1 2024.

The intraocular injection of AXT107 microparticulate suspension will be explored in the DISCOVER study.

HLX04-O has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.

According to the company, Megan Baldwin, PhD, CEO of Opthea Ltd, will provide an overview of the company’s Phase 3 clinical program advancing OPT-302 for the treatment of wet AMD.

Francesca Marassi, PhD, and her collaborators have received a $13 million National Institutes of Health grant to study misplaced calcified deposits that are a misunderstood factor in common diseases of aging, including age-related macular degeneration.

According to the company, initial interim Phase 2 efficacy data is expected to be presented in H1 2024. It also is expected to provide an update regarding Phase 3 pivotal trial plans in Q1 2024 after discussion with the FDA later this year.

Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.

The Icahn School of Medicine at Mount Sinai opened the Center for Ophthalmic Artificial Intelligence and Human Health, which is dedicated to advancing artificial intelligence to offer faster diagnosis and treatment.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.

Eyebiotech noted its AMARONE trial will evaluate the safety and preliminary efficacy of intravitreal EYE103.

RAFARM and BioNanoSim have entered into an agreement to create the company.

Doheny Eye Institute announced Ghosh was recognized by Research to Prevent Blindness and the International Retinal Research Foundation.

According to the company, topline results from the clinical trial are expected by the third quarter of 2024.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

If approved, RVO would be the third indication for Vabysmo in addition to wet age-related macular degeneration and diabetic macular edema.

Efavirenz boosts cholesterol turnover in retina, brain.

Photobiomodulation is an emerging treatment for dry age-related macular degeneration (AMD).

Physician discusses clinical presentations, treatment options for 2 cases.